A Phase 2 Study to Evaluate the Safety and Efficacy of CTP-499 in Type 2 Diabetic Nephropathy Patients
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 170 participants.
Also called NCT01487109
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 170 participants
- Sponsor
- Concert Pharmaceuticals
- Registry
-
NCT01487109
-
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- United States
- Registry status
- Completed
Technical summary
Registry record NCT01487109. Randomized; double masking; primary purpose treatment. Start 2012-01 (registry gives no type); primary completion 2015-01 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Phase 2 Study to Evaluate the Safety and Efficacy of CTP-499 in Type 2 Diabetic Nephropathy Patients
- Condition
- Type 2 Diabetes Mellitus
- Condition
- Chronic Kidney Disease
- Intervention (Drug)
- CTP-499
- Intervention (Drug)
- Placebo
- Lead sponsor
- Concert Pharmaceuticals
Record details
- Record id
cardio:ct-nct01487109- Content hash
49deeddfabfd640171b0c96cd80db66d82a41e3ef34c38845fdc831577af9e03